CharlesN.LandenMDMS

PubMed

• 3 citations
  Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles.
  Kevin Elias, Urszula Smyczynska, Konrad Stawiski, Zuzanna Nowicka, James Webber, Jakub Kaplan, Charles Landen, Jan Lubinski, Asima Mukhopadhyay, Dona Chakraborty, Deni...> ;Nature Communications. 2023 Jun 8
• 7 citations
  Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
  Charles N Landen, Luciana Molinero, Habib Hamidi, Jalid Sehouli, Austin Miller, Kathleen N Moore, Cagatay Taskiran, Michael Bookman, Kristina Lindemann, Charles Anders...> ;Clinical Cancer Research. 2023 May 1
• 4 citations
  Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy.
  Alexandra R Harris, Savieay Esparza, Mohammad S Azimi, Robert Cornelison, Francesca N Azar, Danielle C Llaneza, Maura Belanger, Alexander Mathew, Svyatoslav Tkachenko,...> ;Frontiers in Oncology. 2022 Jan 1
• 2 citations
  Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
  Premal H. Thaker, Liz Y. Han, Aparna A. Kamat, Jesusa M.G. Arevalo, Rie Takahashi, Chunhua Lu, Nicholas B. Jennings, Guillermo N. Armaiz-Pena, James A. Bankson, Murali...> ;Nature Medicine. 2021 Nov 19
• 4 citations
  A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors.
  Gururaj Shivange, Tanmoy Mondal, Evan Lyerly, Sanchita Bhatnagar, Charles N. Landen, Shivani Reddy, Jonathan Kim, Britney Doan, Paula Riddle, Jogender Tushir-Singh> ;Cell Reports. 2021 Nov 2
• 7 citations
  CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer.
  Robert Cornelison, Kuntal Biswas, Danielle C. Llaneza, Alexandra R. Harris, Nisha G. Sosale, Matthew J. Lazzara, Charles N. Landen> ;Cancers. 2021 Oct 9
• 6 citations
  A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer.
  Samantha M. Perez, Julien Dimastromatteo, Charles N. Landen, Kimberly A. Kelly> ;Cells. 2021 Aug 27
• Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.
  Aparna A. Kamat, Mavis S. Fletcher, Lynn M. Gruman, Peter R. Mueller, Adriana Lopez, Charles N. Landen, Liz Y. Han, David M. Gershenson, Anil K. Sood> ;Clinical Cancer Research. 2021 Aug 1
• 4 citations
  Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer
  John S. Lazo, Elizabeth R. Sharlow, Robert Cornelison, Duncan J. Hart, Danielle C. Llaneza, Anna J. Mendelson, Ettore J. Rastelli, Nikhil R. Tasker, Charles N. Landen,...> ;Biomolecules. 2021 Jun 30
• 6 citations
  The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses.
  Burthia E Booker, Adam D. Steg, Stefan Kovac, Charles N. Landen, Hope M. Amm> ;Cancer Biology & Therapy. 2020 Sep 11
• 5 citations
  Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
  C. Bethan Powell, Ramey D. Littell, Charles N. Landen, Sharmila Pramanik, Isabella C. Hamilton, Elizabeth Suh-Burgmann> ;Gynecologic Oncology. 2020 Jan 7
• 31 citations
  Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.
  Stephen Shang, Jiekun Yang, Amir A. Jazaeri, Alexander James Duval, Turan Tufan, Natasha Lopes Fischer, Mouadh Benamar, Fadila Guessous, Inyoung Lee, Robert M. Campbel...> ;Cancer Research. 2019 Sep 15
• 1 citations
  No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.
  Ronald J. Buckanovich, Gordon J. S. Rustin, Shitanshu Uppal, Alexander B. Olawaiye, Joseph L. Kelley, Jessica Berger, Charles N. Landen> ;Journal of Clinical Oncology. 2019 Aug 26
• 9 citations
  Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
  Jung Mi Byun, Dae Sim Lee, Charles N. Landen, Da Hyun Kim, Young Nam Kim, Kyung Bok Lee, Moon Su Sung, Sae Gwang Park, Dae Hoon Jeong> ;Acta Oncologica. 2019 Jul 1
• 89 citations
  A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
  Ilana Chefetz, Edward Grimley, Kun Yang, Linda Hong, Ekaterina V. Vinogradova, Radu M. Suciu, Ilya Kovalenko, David Karnak, Cynthia A. Morgan, Mikhail Chtcherbinine, C...> ;Cell Reports. 2019 Mar 12
• 63 citations
  Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer
  Edith Emmings, Sally A. Mullany, Zenas Chang, Charles N. Landen, Stig Linder, Martina Bazzaro> ;International Journal of Molecular Sciences. 2019 Jan 8
• 16 citations
  FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer
  Kelly M. Kreitzburg, Samuel C. Fehling, Charles N. Landen, Tracy L. Gamblin, Rebecca B. Vance, Rebecca C. Arend, Ashwini A. Katre, Patsy G. Oliver, Robert C.A.M. van W...> ;Cancer Letters. 2018 Nov 1
• 113 citations
  A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily
  Rai, K., Anil Korkut, Sobia Zaidi, Rupa S. Kanchi, Shuyun Rao, Nancy R. Gough, Andre Schultz, Xubin Li, Philip L. Lorenzi, Ashton C. Berger, Gordon Robertson, Lawrence...> ;Cell Systems. 2018 Oct 24
• 27 citations
  A Single Agent Dual Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer
  Gururaj Shivange, Karol Urbanek, Piotr Przanowski, Justin S. A. Perry, James L. Jones, Robert Haggart, Christina Kostka, Tejal Patki, Edward B. Stelow, Yuliya I. Petro...> ;Cancer Cell. 2018 Aug 13
• 249 citations
  Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060))
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Cell. 2018 Aug 9
• 13 citations
  Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal ...
  Anne L. Carlton, Anuradha Illendula, Yan Gao, Danielle C. Llaneza, Adam Boulton, Anant Shah, Roger A. Rajewski, Charles N. Landen, David Wotton, John H. Bushweller> ;Gynecologic Oncology. 2018 May 1
• 11 citations
  Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
  Rebecca C Arend, Angelina I Londoño-Joshi, Abhishek Gangrade, Ashwini A Katre, Chandrika Kurpad, Yonghe Li, Rajeev S Samant, Pui-Kai Li, Charles N Landen, Eddy S Yang,...> ;Oncotarget. 2018 Apr 10
• 1272 citations
  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
  Rai, K., Katherine A Hoadley, Christina Yau, Toshinori Hinoue, Denise M. Wolf, Alexander J. Lazar, Esther Drill, Ronglai Shen, Alison M. Taylor, Andrew D. Cherniack, V...> ;Cell. 2018 Apr 5
• 200 citations
  Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
  Rai, K., Joshua D. Campbell, Christina Yau, Reanne Bowlby, Yuexin Liu, Kevin Brennan, Huihui Fan, Alison M. Taylor, Chen Wang, Vonn Walter, Rehan Akbani, Lauren Averet...> ;Cell Reports. 2018 Apr 3
• 221 citations
  Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
  Rai, K., Franz X. Schaub, Varsha Dhankani, Ashton C. Berger, Mihir Trivedi, Anne B. Richardson, Reid Shaw, Wei Zhao, Xiaoyang Zhang, Andrea Ventura, Yuexin Liu, Donald...> ;Cell Systems. 2018 Mar 28
• Join now to see all